Objective-To evaluate the eVectiveness of a mass screening programme for breast cancer in a French population where hormone replacement therapy (HRT) is common and where mammography is prescribed outside the programme for asymptomatic women. Methods-From 1993 to 1996 inclusive, 41 062 women underwent a first test and 48 275 a second or third test in the Bouches du Rhône programme. Their HRT status was ascertained at the time of the test. False positive and false negative tests were identified at one year follow up. The incidence of interval cancers was estimated up to three years after the screening test. Results-The odds of being detected at screening rather than as an interval cancer within one year of the test was five times greater among non-users of HRT than among users (odds ratio (OR) 5.14 (confidence interval 2.5 to 11.8)). This high reduction in sensitivity among users (71% v 92%) was associated with a very small reduction in specificity at the incident screen only. The incidence of interval cancers among HRT users was 3.5 times that of non-users within the first year after the test and 1.7 times during the following two years. Conclusions-When the early results of a programme have been used to measure its eVectiveness they should be reassessed in populations where HRT is in widespread use. As interval cancers had better prognostic factors in HRT users than in non-users, the eYcacy of a screening programme in such populations should be the subject of further studies. (J Med Screen 1999;6:99-102) 
Screening for breast cancer with mammography can reduce mortality from the disease by at least 29% in women aged over 50 years when it is carried out in a well organised programme. 1 It is widely accepted that this method of prevention is considerably less eYcient, if at all, in women aged less than 50 2 because tumours grow more quickly at this younger age 3 and, also, mammography has a low sensitivity in the dense breasts of young women. 3 4 In recent years hormone replacement therapy (HRT) has been widely prescribed for post-menopausal women for several good reasons, including the prevention of osteoporosis and cardiovascular disease. This treatment increases the density of the breast parenchyma in mammographic imaging and we can anticipate that the sensitivity of mammography will be lower in treated women than in women who have not received HRT. This was confirmed recently by Laya et al in a study carried out in Washington state including almost 9000 women attending a breast screening programme. 5 They showed that both the sensitivity and specificity of screening mammography were lower in treated women. However, this study was carried out in America and data were presented after one year's follow up, because screening takes place annually. Similarly, in the South Derbyshire NHS breast screening programme, Cohen reported that the ratio of screen detected to interval cancers within two years of screening was higher for non-users than for users of HRT. 6 As the use of HRT is steadily increasing in many countries the method of monitoring the early results of a screening programme should probably be revised because they are based on indicators derived from the results of the Swedish two county study before 1980 when the use of HRT was rare. It is therefore timely to analyse the information available from screening programmes carried out in countries where HRT has been prevalent for a longer time.
In France the first pilot breast cancer screening programmes were launched in 1989. Currently, about 40% of the women in the relevant age group are invited to a screening programme. The sole screening modality is a single view mammogram taken every three years. The Bouches du Rhône district, where this study was carried out, was one of the pilot projects. It is suitable setting for evaluation of the eVectiveness of screening in a country where organised screening coexists with spontaneous mammographic testing. 7 In France in 1998, according to a survey by the pharmaceutical industry, the prevalence of HRT use was about 30% among women aged 50-64, and this is likely to increase. Currently, in France women receive oestradiol compounds (transdermal 17 -oestradiol or oral natural oestradiol) with cyclical or continuous combined progestins. 8 Our study aimed at discovering to what extent HRT, as prescribed in France, decreases the eVectiveness of screening mammography.
We also determined whether the targets established to monitor the early results, including interval cancer rates, are achievable in a population in which a large proportion of women receive HRT. 9
Subjects and methods
Our study population included women enrolled in the Bouches du Rhône breast cancer screening programme between 1993 and 1996; this programme started in 1990. The target population was 190 000 women aged 50-69. Every three years women receive an invitation to attend for screening with one view, mediolateral oblique. They may consult the radiologist of their choice in any one of 110 radiology centres that participated in the study. A comprehensive quality assurance programme of all mammography equipment was introduced in 1993, and dual reading of all films is carried out by six expert radiologists specialising in breast imaging. The programme is part of the Europe Against Cancer pilot network for breast cancer screening. The first results were published in 1996 and 1997. 7 10 Between January 1993 and December 1996 41 062 women underwent the first round of screening (the prevalent screen) and 48 275 the second or third round (incident screen). The radiographers asked the participants about their present use of HRT. The type of drugs, dosage route, frequency of administration, and duration of use were not recorded. A total of 74 507 women were non-users of HRT, and 14 830 were users. The percentage of women aged 50-69 taking HRT has risen from 18% in 1993 to 27% in 1996. More than two thirds of users were aged under 60-34% were 50-54 and 36% were 55-59.
The mammography readings were classified as negative or positive; only positive screening mammograms require further assessment. The outcome of all positive screen results is monitored at the coordinating centre by contacting the patient or her doctor. The follow up of screen negative women is carried out from the histological information collected on all breast biopsies performed in the corresponding geographical area through a pathology register held since 1989. Only interval cancers which are not assessed by biopsy are missed by the register (for example, those diagnosed using fine needle aspiration cytology). The completeness of the register has been estimated at approximately 90%.
We shall use the following definitions: Cancers detected are malignant lesions in situ and invasive cancers detected in a screening round. Lobular carcinoma in situ are not considered as cancer.
False positive findings are defined as the absence of a diagnosis of breast cancer within 12 months of a negative screen in women who are recalled. True negative findings are defined as the absence of a diagnosis of breast cancer in women who were not recalled. Interval cancers are defined as cancers occurring within 36 months of a negative screen. Sensitivity is given approximately as the proportion of detected cancers among those that are either detected or occur within 12 months of screening. Specificity is defined as the proportion of negative mammograms among women who do not develop cancer within these same 12 months.
The Mantel-Haenzel method stratified for age and type of screen was used to compare sensitivity and specificity, and a Poisson regression was used to compare the incidence of interval cancers in HRT users and non-users. 11 Table 1 summarises the follow up one year after the prevalent and incident screening rounds for users and non-users of HRT.
Results
The sensitivity was greater among HRT non-users (92%) than among HRT users (71%): the odds of being detected at screening rather than as an interval cancer within the first year after screening was more than five times greater among HRT non-users than among users (odds ratio 5.14 (95% CI 2.5 to 11.8)). There was no evidence of modification of this eVect either by age or by type of screen. The specificity was greater for the incident screen (97.5) than for the prevalent screen (95.3) (p<10 −8 ), as expected, because information from the previous screen is available for the incident screen but not for the prevalent screen. The specificity at the incident screen was slightly lower for HRT users than for nonusers (OR 1.26 (95% CI 1.07 to 1.48)), but there was no diVerence of specificity between the groups at the prevalent screen. Table 2 shows the incidence rate of interval cancers in HRT users and non-users. The difference was highly significant ( 2 =18.0; 1 df) and was not modified by either age or type of screen. The overall relative incidence rate between the two groups was 2.3. It was, however, 3.5 in the first year after screening and only 1.7 in the following years. This diVerence was of borderline significance ( 2 =3.4; 1 df; p=0.065).
Discussion
The Swedish randomised trials carried out between 1976 and 1984 showed a significant 29% reduction in breast cancer mortality among women aged 50-69. 1 The prevalence of HRT use was not reported and was probably low at that time. Laya et al showed that mammography is less specific and less sensitive for the detection of breast cancer in HRT treated women. 5 The study group were women attending a health maintenance programme. About a quarter of them were current HRT users and more than half of the latter used oestrogens alone. In France over the past few years post-menopausal non-hysterectomised women, who were HRT users, were treated with an oestrogen/progestin combination to prevent the risk of developing endometrial cancer.
Recent studies gave information about the eVects of progestagens on breast tissue. Parenchymal density is increased in about one fourth of women who start HRT, especially in those following a combined oestrogen/progestin regimen. [12] [13] [14] [15] A higher incidence of cyst formation or asymmetrical densities can lead to unnecessary recall. 15 Our data provide further information about the sensitivity and specificity of mammography among women treated with a combined HRT regimen and taking part in a breast cancer screening programme.
We found a similar specificity in HRT users and non-users for the prevalent screen and a very slight decrease among HRT users having an incident screen (97.6% v 96.9%). Thurfjell, in the Uppsala Swedish programme, found a decrease in specificity in the second round in women currently using cyclical or continuous combined oestrogens/progestin (94% and 93% v 95% in never users). 16 Laya et al when evaluating a prevalent screen in the United States also showed lower specificity in HRT users (92% v 95% for never users) when a mammogram was defined as "suspicious of malignancy" at the first screening mammogram. 5 Litherland et al showed that a significant fall in recall rate was seen between the prevalent and incident screens in women not taking HRT. 17 This fall was not present in women taking HRT, which suggests that the specificity was lower among HRT users. In our study the recall rate at the incident screen is slightly higher in HRT users than in non-users (3.3% v 2.8%).
Laya has evaluated the decrease in sensitivity with conjugated equine oestrogens mainly used in the United States. We found the same decrease with 17 -oestradiol plus progestin often used in Europe. The observed decrease of sensitivity among HRT users is highly significant in our study (71% v 92%). Our results of the first and subsequent screens with single view mammography are comparable with those of Laya (69% v 94%), who used clinical examination and two view mammography. 5 DiYculties in interpreting screening mammograms of dense breasts are the main reason for the observed decrease in sensitivity. 4 In the study of Stomper et al 52/284 women aged 50-69 had mammographic parenchymal density categorised as very dense (90% or greater dense tissue) in HRT users, compared with 30/343 in non-users. 18 In our programme 17% of women taking hormones had very dense breasts (75% or greater dense tissue) as compared with 9% of women not taking hormones. We did not have information about risk factors which might have influenced the breast density. A study carried out in the same region showed that except for a small weight diVerence these factors are distributed similarly in users and non-users. 8 The greater parenchymal density among HRT users is therefore largely explained by the treatment. Twenty eight per cent of interval cancers in non-users occurred in dense breasts as compared with 39% in users. The reduced quality of mammograms in dense breasts, which adds to the diYculty of detection of small noncalcified masses, may explain these findings. 6 19 Two view mammography would certainly improve cancer detection, 20 but the quantitative improvement in sensitivity and specificity which would be obtained by the addition of a second view in the users group is not known.
The interval cancer rate is a major determinant of the long term benefit of a screening programme. 9 The targets used to monitor the early results of a screening programme were established from the results of screening programmes in which the prevalence of HRT was low. The first results published in the NHS breast screening programme found higher rates of interval cancers than expected, and Beral et al suggested that HRT might have contributed to the diVerence observed in women below the age of 60. 21 Our results highlight the fact that the eVect of HRT on the incidence of interval cancers persists for three years. This excess incidence is only partly real since the baseline incidence is higher in HRT users. 22 However, treated women often benefit from regular medical surveillance. In our study, for example, HRT users were more likely than non-users to have already had a mammogram in the three years before entering the programme (71% v 38%). Mammography is prescribed for breast surveillance outside of the Bouches du Rhône screening programme and allows the detection of interval cancers between screens rather than through symptomatic presentation. This may partly explain the observed excess incidence in the second and third years of follow up. Conversely, the larger excess rate occurring within the first year of follow up is probably attributable to the decreased sensitivity. Three interval cancers out of 19 in the user group and four out of 28 in non-users were detected by mammography during the first year of follow up. The number of cancers in situ was low in interval cancers whatever the HRT status: two in non-users and two in users.
To determine whether the higher incidence of interval cancers among HRT users indicates a large decrease in screening eYcacy, it is necessary to assess the characteristics of these cancers. According to the literature breast cancer in HRT users has a better prognosis than in non-users. 8 23-25 The tumours were smaller in most studies. In addition, they proliferated more slowly and were diVerentiated more easily. The study of Holli et al showed further that size and proliferation advantages were limited to tumours that were positive for the oestrogen receptors. 25 This suggests that HRT caused some tumours, but not all, to grow more slowly. More importantly for the present discussion they showed that the better prognosis was independent of the detection mode (screening v symptoms).
In our study the percentage of small (<10 mm) invasive interval cancers occurring within the first year was far greater in HRT users than in non-users (46% v 12%); in contrast, large tumours (>20 mm) are more common in the interval cancers of non-users (37% v 16%). This proportion of small invasive tumours amongst interval cancers in the users group closely approximates screen detected cancers. Better awareness of the women using HRT may partly explain this finding. Furthermore, the incidence of well diVerentiated interval cancers (grade I) was higher in the user group (28% v 13%) than among the non-users. Laya et al found that the seven interval cancers in the HRT users in their study were all >15 mm, 5 but this was not found in our larger study.
Considering the evidence as a whole, we conclude that although the early indicators of screening eYcacy among HRT users are poor, it cannot be deduced from this that screening of a population with a high prevalence of HRT use would not reduce mortality from breast cancer. The 23% reduction in sensitivity might well be compensated for by a similar improvement in the long term survival of women with interval cancers. Screening in HRT users tends to detect cancer at an early stage in non-dense breasts. It is not known, however, whether if undetected, these cancers would have the same aggressiveness as those that are missed in dense breasts. This information is essential to understand what screening is achieving in HRT users. Further studies are needed to monitor screening programmes in populations including a large proportion of HRT users.
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